In 2026, the global biopharmaceutical industry enters a new phase of high-quality development. Cutting-edge fields such as generative AI-aided drug discovery, in vivo gene editing and TIL cell therapy are accelerating breakthroughs, driving the upgrading of standards throughout the pharmaceutical chain. As a core link, pharmaceutical water treatment is critical to ensuring the safety and efficacy of biological products, with rising market demand. Data shows the global biopharmaceutical water treatment equipment market is expected to grow 18% year-on-year in 2026, with compliance and stability of WFI preparation and disinfection equipment as core selection criteria for pharmaceutical enterprises.
International authorities such as FDA and EMA have tightened WFI control standards, requiring full-process pyrogen-free and traceability, forcing multi-effect water distillers and UV disinfection equipment to upgrade towards intelligence and standardization. The flange pressure of UV disinfection equipment is strictly controlled at 2-3 bar to ensure sealing performance, avoid secondary pollution and meet sterile production needs.
High efficiency, energy saving and full-life-cycle services have become industry consensus, and multi-effect water distillers with eight or more effects (thermal utilization efficiency ≥82%) are mainstream. Hebei Guanyu Environmental Protection provides water treatment equipment complying with USP and EP standards, as well as IQ/OQ/PQ verification services, helping pharmaceutical enterprises adapt to water needs of emerging scenarios such as AI R&D and cell therapy.
